$0.86
1.62% today
Nasdaq, Feb 28, 04:46 pm CET
ISIN
US4169061052
Symbol
HBIO
Sector
Industry

Harvard Bioscience, Inc. Stock price

$0.85
-0.95 52.78% 1M
-2.17 71.85% 6M
-1.26 59.72% YTD
-3.57 80.77% 1Y
-4.55 84.26% 3Y
-2.44 74.16% 5Y
-4.61 84.43% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.04 4.30%
ISIN
US4169061052
Symbol
HBIO
Sector
Industry

Key metrics

Market capitalization $37.07m
Enterprise Value $78.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 91.99
EV/Sales (TTM) EV/Sales 0.80
P/S ratio (TTM) P/S ratio 0.38
P/B ratio (TTM) P/B ratio 0.57
Revenue growth (TTM) Revenue growth -13.15%
Revenue (TTM) Revenue $97.73m
EBIT (operating result TTM) EBIT $-4.55m
Free Cash Flow (TTM) Free Cash Flow $850.00k
Cash position $4.57m
EPS (TTM) EPS $-0.33
P/E forward negative
P/S forward 0.40
EV/Sales forward 0.83
Short interest 2.24%
Show more

Is Harvard Bioscience, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Harvard Bioscience, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Harvard Bioscience, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Harvard Bioscience, Inc. forecast:

Buy
100%

Financial data from Harvard Bioscience, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
98 98
13% 13%
100%
- Direct Costs 46 46
12% 12%
47%
52 52
14% 14%
53%
- Selling and Administrative Expenses 38 38
4% 4%
39%
- Research and Development Expense 11 11
2% 2%
11%
2.49 2.49
72% 72%
3%
- Depreciation and Amortization 7.04 7.04
2% 2%
7%
EBIT (Operating Income) EBIT -4.55 -4.55
377% 377%
-5%
Net Profit -14 -14
337% 337%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Harvard Bioscience, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harvard Bioscience, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity
Neutral
GlobeNewsWire
4 days ago
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Neutral
GlobeNewsWire
about 2 months ago
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET.
More Harvard Bioscience, Inc. News

Company Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Head office United States
CEO James Green
Employees 416
Founded 1901
Website www.harvardbioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today